Generic Name: entecavir

Pronunciation: BEAR-ah-klude

Abbreviation: ETV

Other Market Name: N/A

Drug Class: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

Company: Bristol-Myers Squibb

Approval Status: Approved

Generic Version Available: Yes

Experimental Code: N/A


Drug Indication

FDA-approved for the treatment of chronic hepatitis B infection in adults and children at least 2 years old with evidence of hepatitis B viral replication and active liver inflammation or damage. Baraclude is not recommended for persons coinfected with HIV/HBV who are not also receiving highly active antiretroviral therapy (HAART).


General Info

  • Baraclude was approved by the U.S. Food and Drug Administration for use by adults with chronic hepatitis B on March 29, 2005. Approved for children ≥ 2 years on March 20, 2014.
  • In clinical studies, 70 to 72 percent of participants with compensated liver disease who had no prior treatment showed improved liver biopsy results after 48 weeks of therapy.


Dosage

Adult Dose:

Age 16 years and older and no prior treatment with nucleoside-inhibitors: 0.5 mg once daily. If lamivudine- or telbivudine-resistant: 1 mg once daily. For those with decompensated liver disease: 1 mg once daily. Dosage adjustment is recommended for people with kidney disease. Take on empty stomach (at least two hours after a meal and two hours before the next meal).

Pediatric Dose:

Children 2 years and older and weighing at least 10 kg, no prior treatment with nucleoside inhibitors and lamivudine-experienced: weight-based dosing. Take on empty stomach (at least two hours after a meal and two hours before the next meal).

Dosing Info: Treatment length is indefinite and depends on clinical outcomes. Do not change your dose or stop taking Baraclude without talking to your medical provider.


Side Effects

  • The most common side effects are headache, fatigue, dizziness and nausea. Less frequently reported side effects include insomnia, diarrhea and stomach upset.
  • Baraclude may cause severe liver problems or a serious condition called lactic acidosis (buildup of acid in the blood).


Drug Interactions

  • Before taking this medication, tell your medical provider and pharmacist about any drugs, supplements and herbs you take, whether prescribed, over-the-counter or illicit.
  • Baraclude may interact with drugs that are eliminated by the kidneys.
  • Additional drug-drug interactions may occur; these are listed in Baraclude’s full prescribing information. Potential interactions are listed at
    hep-druginteractions.org.


Other Info

  • There are no adequate, well-controlled studies in pregnant women who have taken Baraclude. Baraclude should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • The safety of breast feeding while taking Baraclude has not been established, and it is recommended that Baraclude be discontinued if breast-feeding.


For More Info: http://www.baraclude.bmscustomerconnect.com

Co-Pay Program Info: https://www.hepmag.com/basics/hepatitis-b-basics/paying-hepatitis-b-treatment

Patient Assistance Program Info: https://www.hepmag.com/basics/hepatitis-b-basics/paying-hepatitis-b-treatment

Last Reviewed: March 4, 2019